Association of proprotein convertase subtilisin/kexin type-9 inhibitors with risk of nonmelanoma skin cancer: a retrospective cohort study
Our study indicated that patients with ASCVD taking PCSK9 inhibitors have a lower risk of incident NMSC than those not taking PCSK9 inhibitors.
Authors
- Sheng‐Hsiang Ma (ORCID: https://orcid.org/0000-0003-1160-5083)
- Wei‐Chuan Chang (ORCID: https://orcid.org/0009-0009-8781-9708)
- Yi‐Ju Chen (ORCID: https://orcid.org/0000-0001-5057-8060)
- Li‐Wei Lo (ORCID: https://orcid.org/0000-0001-9102-227X)
- Tai‐Li Chen (ORCID: https://orcid.org/0000-0002-5761-8114)
- Cheng‐Yuan Li (ORCID: https://orcid.org/0000-0002-3185-4995)
- Chen‐Yi Wu
- Wei‐Ting Wang (ORCID: https://orcid.org/0000-0002-2064-9523)
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
- Taichung Veterans General Hospital (TW)
- Public Health Institute (US)
- Buddhist Tzu Chi Medical Foundation (US)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1093/bjd/ljae438
- Citations
- 7
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.64